Izdavanjeto nalekovite na lekarski retsept ili bez retsept ima implikatsii nesamo vrz bezbednosta na patsientot i dostapnosta do lekovite tukui na odgovornoto upravuvanje so zdravstvenite troshotsi. Poagjajkjiod aspekt na bezbednosta na patsientite, dostapnosta do lekovitekako i zachuvuvanjeto na javnoto zdravje i Sovetot na Evropaodnosno negovite tela odgovorni za farmatsevtskata grizha sezainteresirani za kharmonizatsija na natsionalnite zakonskiodredbi povrzani so klasifikatsijata na lekovite spored nachinotna izdavanje. Tokmu od ovie prichini Ministerskiot komitet nazemjite chlenki na Partsijalniot dogovor na poleto na sotsijalnotoi javnoto zdravje vo april 2007 godina ja usvoi Rezolutsijata ResAP(2007)1 za klasifikatsija na lekovi spored nachinot na izdavanje.Pri toa na vladite na zemjite chlenki, potpisnichki na Partsijalniotdogovor vo oblasta na sotsijalnoto i javnoto zdravje soglasnoRezolutsijata se dadeni preporaki koi se se odnesuvaat na: >> dostavuvanje na podatotsi za: klasifikatsijata na lekovitespored nachinot na izdavanje na redovna osnova>> primenuvanje na opshtite kriteriumi za klasifikatsija nalekovite spored nachinot na izdavanje kako shto toa e utvrdenovo apendiksite koi proizleguvaat od rezolutsijata ResAP(2007)1 kako i >> prifakjanje na opshtite kriteriumi za minimumotinformatsii shto treba da gi sodrzhi eden retseptPreporakite koi proizleguvaat od Rezolutsijata ne pretstavuvaatzakonska obvrska no sepak se legalni instrumenti koi vo sebesodrzhat i politichka poraka.Vo ramkite na Sovetot na Evropa postoi Komisija za kla si fi ka -tsija na lekovi spored nachinot na izdavanje i istata raboti podvodstvo na Evropskiot Direktorat za Kvalitet na lekovi (EDQM) voStrazbur. Vo svojata rabota ovaa komisija koristi nauchni pristapii metodi imajkji gi pri toa vo predvid farmakoloshkite osobinina lekot, prashanjata za direktnite i indirektnite rizitsi (far m a -ko vi gilantsata), zloupotrebata na lekovite kako i drugi prashanjaod znachenje za javnoto zdravje. Ovaa Komisija svoite preporaki poodnos na klasifikatsijata na lekovite spored nachinot na izdavanjegi dava na godishno nivo i istite se objavuvaat na veb stranata naEDQM. Iako ovie preporaki ne se pravno obvrzuvachki vo sekojsluchaj pretstavuvaat dobar osnov za referentsa pri postapkite naklasifikatsija na lekovite spored nachinot na izdavanje za bilokoja zemja od Evropskata Unija i poshiroko. Imajkji go vo predvidgorenavedenoto mozhe da se zakluchi deka segashnata regulativa voRepublika Makedonija (chlen 13 od Zakonot za lekovi i meditsinskipomagala kako i Pravilnikot za nachinot na propishuvanje iizdavanje na lekovi na retsept) vo odnos na klasifikatsijata nalekovite spored nachinot na izdavanje e vo soglasnost soEvropskata regulativa. Doneseniot Pravilnik koj proizleguva odZakonot za lekovi istotaka ni dava mozhnost da gi implementiramepreporakite kako i kriteriumite vostanoveni vo apendiksite naRezolutsijata ResAP(2007)1 za klasifikatsijata na lekovite sporednachinot na izdavanje . Kako i da e evidentno e deka na globalnonivo klasifikatsionite praksi se razlikuvaat od zemja do zemja ivo polza na zachuvuvanje na javnoto zdravje kharmonizatsija na ovapole bi bila pozhelna, posebno koga se raboti za lekovite koimozhat da se izdadat i bez lekarski retsept (OTTs-lekovite).KORISTENA LITERATURA1. Resolution ResAP(2007)1 on the classification of medicines as regards theirsupply2. Zakon za lekovi i meditsinski pomagala (http://www.reglek.com.mk)3. Pravilnik za nachinot na propishuvanje i izdavanje na lekovi na retsept(http://www.reglek.com.mk)HPLC DETERMINATION OF KETOPROFENRESIDUES ON MANUFACTURING EQUIP-MENT SURFACES IN CLEANING VALIDATIONPROCESSKaterina Kocova, Irina Batkovska Borozanova, De-spina Efremova , Gordana Trendovska Serafi-movskaQuality Control Department, Pharmaceutical Company "Replekfarm",DOOEL, Kozle 188, Skopje, Republic of Macedonia INTODUCTIONIn the pharmaceutical industry, cleaning validation is an essential partof the production of drugs and active pharmaceutical ingredients.Cleaning validation is a process of providing documented evidencethat the cleaning methods used for the equipment in the manufac-ture of pharmaceutical products, consistently controls potential car-ryover of a product into a subsequent product to a level which is belowpredetermined level of acceptability.In many cases the same equipment is used for manufacturing of dif-ferent pharmaceutical products. Well defined cleaning procedure mustbe used to avoid any contamination of a subsequent product withresidues of a previous product, detergents and microbial contami-nants.MATERIAL AND METHODSVarian HPLC System was used, equipped with Varian Prostar 240pump, Varian 325 LC detector and Galaxie1.9.301.220 software fordata handling.The experiments were carried out by RP- HPLC using LiChrospherO RP18, (125 x 4 mm i.d.) column.The HPLC system was operated at isoc-ratic mode using mobile phase composed of solvent A (20mM KH2PO4,pH-3.5) and acetonitril as solvent B - in ratio 50% : 50%. .The tempe-rature was 35degC and UV detection was at 254 nm.90Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKI ANALIZI / OBEZBEDUVANjE KVALITET / REGULATIVA poster prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVORESULTS AND DISCUSSIONThe goal of this study is to develop a sensitive HPLC method for de-termining the residues of Ketoprofen on the surfaces equipment, usedin manufacturing process, thus controlling the cleaning methods. ThePharmacopoeia HPLC method was appropriately adapted and vali-dated according to ICH guidelines. The method was validated throughdetermining these validation characteristics: selectivity, linearity,pre-cision,accuracy, quantification limit and detection limit. Achived va-lues for LOD of 0,05 mg/ml and for LOQ of 0,2 mg/ml , indicate that theproposed HPLC method is enough sensitive for determining the esta-blished product residual limits. Predetermined levels of acceptabilityfor Ketoprofen residues were in the range from 4.9 ppm to 6.5 ppm, de-pends on the used manufacture equipement.The recovery and its RSD are very important parameters used to eva-luate the effectivness and credibility of the cleaning process.The directsurface sampling method (swab method) was used. It was defined thepercentage of swab recovery process using the cupons that mimic thesurface equipment . The obtained % recovery of 85.51 confirmed theappropriatness of the cleaning method.CONCLUSIONIn conclusion , the developed HPLC method for determination of re-sidues of Ketoprofen on manufacturing equipment surface is enoughsensitive and can be used in routine analyses in cleaning validationprocess.REFERENCES1. Cleaning Validation Manual, Syed Imtiaz Haider, Ph.D., Erfan Syed Asif Ph.D.,2010, USA2. FDA, Guide to Inspections of Validation of Cleaning Processes, (Validation ofcleaning Processes 7/93).3. Anex 15 GMP, 2001;OPREDELUVANjE NA KETOPROFENREZIDUI OD POVRShINI NAPROIZVODNA OPREMA SO HPLC METODVO PROTsES NA VALIDATsIJA NAChISTENjE Katerina Kochova, I. Batkovska Borozanova, D.Efremova, G. Trendovska Serafimovska Sektor Kontrola na kvalitet, Replekfarm DOOEL, ul.Kozle 188,Skopje, R.Makedonija VOVEDVo farmatsevtskata industrija validatsija na chistenje pretstavuvavazhen segment vo proizvodtsvo na lekovi i aktivni supstantsi. PodValidatsija na chistenje se podrazbira protses koj kje obezbedi sosoodvetna postapkata na chistenje na proizvodnata oprema, da seotstranat ostatotsite na aktivni komponenti pod utvrdenitelimiti na prifatlivost. Vo mnogu sluchai, istata proizvodna oprema mozhe da se koristi zaproizvodstvo na razlichni proizvodi. Za da se izbegnekontaminatsija na nareden proizvod (od pretkhoden proizvod,detergenti,mikroorganizmi) neopkhodna e adekvatna postapka nachistenje.MATERIJALI I METODIPri kfantifikatsijata se koristi HPLC sistem Varian, opremen sotertsierna pumpa, UV-VIS detektor, avtosempler, termostat zakolona kontroliran preku softverski program Galaxy Data system. Koristena e kolona LiChrospherO RP 18(125 x 4 mm i.d.) . Primenete izokratski nachin na khromatografiranje so mobilna fazasostavena od rastvoruvach A (20mM KH2PO4 ,pH-3.5) i rasvoruvach B- atsetonitril vo odnos 50% :50%. Upotrebena e temperatura od35degC i detektsija od 254 nm.REZULTATI I DISKUSIJATselta na ovaa studija e da se razvie senzitiven HPLC metod zaopredeluvanje na rezidui od Ketoprofen na povrshina odproizvodna oprema, za da se kontrolira protsesot na validatsijana chistenje. Farmakopejskiot HPLC metod za opredeluvanje naKetoprofen EP , beshe soodvetno adaptiran i validiran vo odnosna selektivnost, linearnost, pretsiznost/tochnost kako isenzitivnost pri shto bea opredeleni limitot na detektsija -LODi limitot na kvantifikatsija -LOQ. Dobienite vrednosti za LODod 0,05 mg/ml i 0,2 mg/ml za LOQ, ukazhuvaat deka predlozheniotHPLC metod e dovolno osetliv za da gi determinira utvrdenitelimiti na prifatlivost na rezidui od Ketoprofen. Limiti naprifatlivost za rezidui na Ketoprofen se od 4,9 ppm do 6,5 ppm, vo zavisnost od koristenata proizvodna oprema. Postapkata na zemanje na bris od poedini delovi na proizvodnataoprema , beshe pretkhodno utvrdena preku opredeluvanje naanalitichkiot prinos "Swab Recovery" na spajkuvani inoksniplochi- kuponi (na tri kontsentratsiski nivoa po dve svobuvanja nasekoe nivo )chij materijal soodvetstvuva na proizvodnata oprema.Tekhnikata na zemanje na brisevi beshe optimizirana , so tsel da sedobie prifatliv analitichki prinos na Ketoprofen odspajkuvanite chelichni povrshini. Prosechniot analitichki prinos od85,5% ukazhuva deka primenatiot nachin na zemanje na brisevi esoodveten za studijata na validatsija na chistenje. ZAKLUChOKUpotrebeniot HPLC metod e dovolno senzitiven i mozhe da sekoristi vo rutinska analiza kako del od protsesot na validatsijana chistenje .LITERATURACleaning Validation Manual, Syed Imtiaz Haider, Ph.D., Erfan Syed Asif Ph.D., 2010,USAFDA, Guide to Inspections of Validation of Cleaning Processes, (Validation ofcleaning Processes 7/93).Anex 15 GMP, 2001;91PHARMACEUTICAL ANALYSIS / QUALITY ASSURANCE / REGULATORY AFFAIRS poster presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONMacedonian Pharmaceutical Bulletin 57 (suppl), 2011FARMAKOEKONOMIJA / SOTsIJALNA FARMATsIJA /FARMAKOINFORMATIKAoralni prezentatsiiPHARMACOECONOMY / SOCIAL PHARMACY / PHARMACOINFORMATICSoral presentationsPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOHEALTH ECONOMIC ASPECTS OF DIABETESMarcin Czech1Department of Pharmacoeconomics, Medical University of Warsaw2Europe East Regional Office, Novo NordiskDiabetes mellitus is one of the most important clinical problems inthe world today being the 4th leading cause of death in Europe. Ac-cording to information from the World Health Organization (WHO)more than 180 million people worldwide have diabetes. In 2005, an es-timated 1.1 million people died from diabetes. Almost half of diabetesdeaths occur in people under the age of 70 years and 55% are inwomen. Without introducing effective projects within the publichealth domain, diabetes-related deaths will increase by more than 50%in the next 10 years. More than 32 million European Union (EU) citizens have diabetes,meaning 9% of the total population.An additional 32 million citizens (8,8% of the population) suffer fromimpaired glucose tolerance (pre-diabetes).This situation will deteriorate in the future, with an estimated 38,3million adult citizens with diabetes in 2030.Type 2 diabetes, accounting for about 85-90% of all diabetes in Eu-rope, decreases life expectancy by 5-10 years. High prevalence and incidence have a substantial social impact, es-pecially in less developed countries like those of Central and EasternEurope. Health economic aspects of diabetes can be considered from at leastthree stand points; global burden of the disease, cost- effectiveness ofdifferent interventions and cost-utility, where quality of life aspectsplay their role.Costs of illness include not only costs associated with prevention, di-agnosis, and treatment (direct costs) but also indirect costs regardingreduced or lost productivity. In most EU Member States, diabetes is responsible for over 10% ofhealthcare expenditure; a figure sometimes climbing as high as 18,5%.In total, diabetes costs the EU at least 77 billion EUR a year.The general healthcare cost for an EU citizen with diabetes is on av-erage 2.100 EUR a year.Despite strong beliefs, it is not the treatment of diabetes that coststhe most; it is the treatment of its complications. A vast majority ofdiabetic patients remain uncontrolled, which increases costs of micro-and macro-angiopathic complications (including blindness, neu ropa t -hy, diabetic foot, and arteriosclerosis of the coronary and the renalarteries). In other words, the longer one waits for treatment, the moreit will cost.